A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [live, attenuated]) in Healthy Adults
Latest Information Update: 11 May 2025
At a glance
- Drugs V 181 (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Acronyms V181-003
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
Most Recent Events
- 17 May 2024 Status changed from active, no longer recruiting to completed.
- 27 Jun 2023 Planned End Date changed from 24 Jun 2024 to 6 May 2024.
- 11 May 2023 Planned primary completion date changed from 14 Aug 2023 to 8 Jun 2023.